Literature DB >> 11859427

Potential limitations of transcription terminators used as transgene insulators in adenoviral vectors.

M Buvoli1, S J Langer, S Bialik, L A Leinwand.   

Abstract

The presence of adenoviral cis-elements interfering with the activity of tissue-specific promoters has seriously impaired the use of transcriptional targeting adenoviruses for gene therapy purposes. As an approach to overcome this limitation, transcription terminators were previously employed in cultured cells to insulate a transgene promoter from viral activation. To extend these studies in vivo, we have injected into heart and skeletal muscle, adenoviruses containing the human growth hormone terminator and the cardiac-specific alpha-myosin heavy chain promoter (alphaMyHC) driving the chloramphenicol acetyltransferase (CAT) reporter gene. Promoterless CAT constructs were also tested to study interfering viral transcription and terminator activity. Here we demonstrate that the presence of a terminator can produce undesirable effects on the activity of heterologous promoters. Our analysis shows that in particular conditions, a terminator can reduce the tissue specificity of the transgene promoter. By RNAse protection assay performed on cardiac myocytes, we also show that adenoviral elements can direct high levels of autonomous transcription within the E1A enhancer region. This finding supports the model that passive readthrough of the transgene promoter is responsible for loss of selective expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859427     DOI: 10.1038/sj.gt.3301640

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  5 in total

1.  Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted.

Authors:  Masato Yamamoto; Julia Davydova; Koichi Takayama; Ramon Alemany; David T Curiel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes.

Authors:  Vladimir P Torchilin; Tatyana S Levchenko; Ram Rammohan; Natalia Volodina; Brigitte Papahadjopoulos-Sternberg; Gerard G M D'Souza
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-05       Impact factor: 11.205

Review 3.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

4.  Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Authors:  Charles Lu; David J Stewart; J Jack Lee; Lin Ji; Rajagopal Ramesh; Gitanjali Jayachandran; Maria I Nunez; Ignacio I Wistuba; Jeremy J Erasmus; Marshall E Hicks; Elizabeth A Grimm; James M Reuben; Veerabhadran Baladandayuthapani; Nancy S Templeton; John D McMannis; Jack A Roth
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

5.  Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.

Authors:  Bingbing Dai; Shaoyu Yan; Humberto Lara-Guerra; Hiroyuki Kawashima; Ryo Sakai; Gitanjali Jayachandran; Mourad Majidi; Reza Mehran; Jing Wang; B Nebiyou Bekele; Veerabhadran Baladandayuthapani; Suk-Young Yoo; Ying Wang; Jun Ying; Feng Meng; Lin Ji; Jack A Roth
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.